Charles River Laboratories (CRL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Charles River Laboratories (CRL) has a cash flow conversion efficiency ratio of 0.014x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($41.08 Million) by net assets ($2.99 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CRL days of operational coverage to measure how many days the company can operate on defensive assets alone.
Charles River Laboratories - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Charles River Laboratories's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Charles River Laboratories Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Charles River Laboratories ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SouthState Corporation
NASDAQ:SSB
|
0.014x |
|
Securitas AB
ST:SECU-B
|
0.095x |
|
ORKLA ADR/1 NK 625
F:OKL0
|
0.071x |
|
WT Microelectronics Co Ltd
TW:3036
|
-0.075x |
|
ENN ENERGY HLD.UNS.ADR/25
F:XGH0
|
N/A |
|
Aecom Technology Corporation
NYSE:ACM
|
0.029x |
|
Alexandria Real Estate Equities Inc
NYSE:ARE
|
0.010x |
|
Guobo Electronics Co. Ltd. A
SHG:688375
|
N/A |
Annual Cash Flow Conversion Efficiency for Charles River Laboratories (1998–2025)
The table below shows the annual cash flow conversion efficiency of Charles River Laboratories from 1998 to 2025. For the full company profile with market capitalisation and key ratios, see CRL company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.21 Billion | $737.65 Million | 0.230x | +9.70% |
| 2024-12-31 | $3.51 Billion | $734.58 Million | 0.209x | +12.03% |
| 2023-12-31 | $3.66 Billion | $683.90 Million | 0.187x | -8.80% |
| 2022-12-31 | $3.02 Billion | $619.64 Million | 0.205x | -30.18% |
| 2021-12-31 | $2.59 Billion | $760.80 Million | 0.294x | +15.12% |
| 2020-12-31 | $2.14 Billion | $546.58 Million | 0.255x | -11.65% |
| 2019-12-31 | $1.67 Billion | $480.94 Million | 0.289x | -12.45% |
| 2018-12-31 | $1.34 Billion | $441.14 Million | 0.330x | +10.90% |
| 2017-12-31 | $1.06 Billion | $316.26 Million | 0.297x | -14.93% |
| 2016-12-31 | $853.78 Million | $298.32 Million | 0.349x | -6.59% |
| 2015-12-31 | $765.56 Million | $286.36 Million | 0.374x | +4.94% |
| 2014-12-31 | $704.35 Million | $251.05 Million | 0.356x | +14.37% |
| 2013-12-31 | $664.66 Million | $207.14 Million | 0.312x | -9.58% |
| 2012-12-31 | $603.20 Million | $207.90 Million | 0.345x | -11.16% |
| 2011-12-31 | $529.14 Million | $205.28 Million | 0.388x | +58.09% |
| 2010-12-31 | $688.73 Million | $169.01 Million | 0.245x | +49.81% |
| 2009-12-31 | $1.37 Billion | $225.04 Million | 0.164x | -29.82% |
| 2008-12-31 | $1.20 Billion | $279.95 Million | 0.233x | +53.05% |
| 2007-12-31 | $1.86 Billion | $284.25 Million | 0.152x | +48.85% |
| 2006-12-31 | $1.60 Billion | $164.37 Million | 0.102x | -20.50% |
| 2005-12-31 | $1.84 Billion | $236.70 Million | 0.129x | +3.35% |
| 2004-12-31 | $1.48 Billion | $184.83 Million | 0.125x | -52.17% |
| 2003-12-31 | $474.80 Million | $123.77 Million | 0.261x | -26.68% |
| 2002-12-31 | $375.94 Million | $133.66 Million | 0.356x | +50.84% |
| 2001-12-31 | $302.50 Million | $71.30 Million | 0.236x | -9.08% |
| 2000-12-31 | $130.26 Million | $33.77 Million | 0.259x | +175.79% |
| 1999-12-31 | $-109.84 Million | $37.57 Million | -0.342x | -254.24% |
| 1998-12-31 | $168.56 Million | $37.38 Million | 0.222x | -- |
About Charles River Laboratories
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in … Read more